Nalu Medical, Inc.
- Industry
- Medical Device
- Founded Year
- 2014
- Headquarters
- Carlsbad, California, United States
- Employee Count
- 270
Key People
- Thomas A. West - President & Chief Executive Officer
- Lee Hartley - Chief Technical Officer
- Patrick Martin - Vice President, Clinical Affairs
- Chelsea Gutierrez - Vice President, Regulatory Affairs & Quality Assurance
- Michael D. Tutera - Vice President, Market Access
- Bick Sellers - Chief People Officer
- J.P. Timm - Vice President, Operations
- Jeff Swiecki - Chief Financial Officer
- Allen Meacham - Chief Revenue Officer
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with significant backgrounds in the medical technology sector.
The presence of multiple successful MedTech entrepreneurs in the leadership team enhances the company's strategic direction and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: The Nalu Neurostimulation System addresses a significant unmet need in chronic neuropathic pain management.
Chronic neuropathic pain is a prevalent condition with limited effective treatment options. Nalu's innovative approach offers a compelling solution.
- Competition
-
Aspect: Very crowded + Strategics
Summary: The neurostimulation market is highly competitive, with several established players.
Competing against well-established companies with extensive resources poses challenges for market penetration and growth.
- Technical Challenge
-
Aspect: Predictable
Summary: The technology involves moderate complexity with predictable development pathways.
While developing implantable neurostimulation devices involves technical challenges, Nalu's experienced team is well-equipped to handle them.
- Patent
-
Aspect: Strong
Summary: Nalu holds a robust patent portfolio protecting its innovative technologies.
A well-established patent portfolio safeguards the company's innovations and enhances its market position.
- Financing
-
Aspect: Well-funded
Summary: The company has secured substantial funding from reputable investors.
Significant investments from prominent venture capital firms provide the financial resources necessary for product development and commercialization.
- Regulatory
-
Aspect: 510k/PMA + Reimbursement
Summary: The Nalu Neurostimulation System has received FDA clearance for SCS and PNS indications.
Achieving FDA clearance demonstrates the product's safety and efficacy, enabling commercialization in the U.S. market.
Opportunity Rollup
- Odds of Success
- 3.75
- Peak Market Share
- 5.1
- Segment CAGR
- 9.1%
- Market Segment
- Neuromodulation Devices
- Market Sub Segment
- Spinal Cord and Peripheral Nerve Stimulation
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.26 |
| 2 | 0.76 |
| 3 | 1.78 |
| 4 | 3.57 |
| 5 | 5.10 |
Key Takeaway
Nalu Medical's innovative neurostimulation system addresses a significant clinical need in chronic pain management, supported by a strong team and substantial funding, positioning the company for success in a competitive market.